x
CME-Tagline

A Hot Potato in Health Care: Whose Responsibility is it to Advocate for Cancer Screenings for SGM Patients?

CMEO BriefCase

Premiere Date: Tuesday, May 17, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Wednesday, May 17, 2023

Faculty


Don S. Dizon, MD, FACP, FASCO Don S. Dizon, MD, FACP, FASCO (Moderator)
(he/him)
Professor of Medicine and Professor of Surgery, Brown University
Director, The Pelvic Malignancies Program and Hematology-Oncology Outpatient Clinics, Lifespan Cancer Institute
Head, Community Outreach and Engagement, Legoretta Cancer Institute at Brown University
Director, Medical Oncology and the Oncology Sexual Health First Responders Clinic
Rhode Island Hospital
Providence, RI

Gwendolyn P. Quinn, PhD Gwendolyn P. Quinn, PhD 
(she/her)
Professor and Livia Wan MD Endowed Chair
Department of Obstetrics and Gynecology
New York University Grossman School of Medicine
New York, NY

Statement of Need

Gendered and heterosexual presumptive care settings are commonplace in health care and alienate sexual and gender minority (SGM) patients from receiving routine cancer screenings. Gendered references to gynecologic and breast cancers as women’s cancer, and prostate cancer as men’s cancer, is deeply rooted into the health care system. By disentangling gender from cancer and breaking down heteronormative assumptions, clinicians can provide equitable care to all patients, and critically, improve outcomes for SGM patients. National surveys and published literature show that SGM patients often delay cancer screenings and care for fear of stigma or mistreatment, which may result in later cancer diagnoses and poorer outcomes. Health care professionals who are trained in culturally relevant and humble care engage patients in discussions about the need for cancer screenings. Providing equitable care to SGM patients requires changing the practice environment, patient communications, and information gathering processes to create an inclusive, affirming, and welcoming experience for diverse genders and sexual orientations. These changes can only be effective if the entire team, clinical and non-clinical staff alike, are trained in culturally relevant and humble education as they interact and care for SGM patients.

In this CMEO BriefCase, faculty will use case-based learning to connect gendered and heterosexual presumptive care settings to health inequities and poor outcomes for SGM patients, and then, provide examples of how to create welcoming, inclusive environments and practice cultural humility with patients.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Identify techniques for providing culturally relevant communication regarding screening needs to SGM.

Financial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Target Audience

Physicians, PAs, nurse practitioners, nurses and pharmacists specializing in oncology, obstetrics, gynecology, infectious disease, and/or primary care

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Dizon reports the following financial relationships:

Consultant: DSMB/IDMC activities for AstraZeneca and Clovis Oncology.

Research Support: Bristol Myers Squibb (institutional support) and Pfizer Inc.

Other financial or material support: Board member for the LGBTQ Cancer Network.

Dr. Quinn reports the following financial relationships:

Consultant: Flo Health, Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:

  • Michael Franks, APRN, AGACNP-BC, FNP-BC
  • Julie Strickland, PharmD (planning committee)
  • David Modrak, PhD (planning committee)
  • Thomas Mitchell (planning committee)
  • Kathleen Blake, PhD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)


  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    This document was last modified on:

    BC-061-051722-44